Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Docket Includes Four Cases Impacting Pharma Industry

Executive Summary

Helsinn v. Teva and Merck v. Albrecht directly involve pharma firms while another case addresses America Invents Act. Solicitor General to weigh in on two other cases. Petitions pending on Maryland pricing law, Amgen PCSK9 suit.

You may also be interested in...



Gilead False Claims Case: Government Opposes Supreme Court Review But Thinks Suit Should Be Tossed

US Solicitor General says facts lacking on what government knew about alleged product misrepresentations; FDA may be burdened with discovery requests if suit proceeds to discovery and trial.

Brand Vs. Generic Supreme Court Fight: Does Sale Of Secret Invention Bar Its Patenting?

In case with potentially broad ramifications for biopharma partnerships, high court will hear arguments Dec. 4 on whether America Invents Act changed the "on-sale bar" to patentability to allow inventions that are sold to be patented if their details are not publicly disclosed.

Restasis Patent Review Back On Track As Federal Circuit Quashes Mohawk Tribe's Sovereign Immunity Claim

Appeals court says inter partes review is more like an agency enforcement action than a civil suit and thus tribal immunity does not apply to the proceeding; PTAB now to determine patentability of Restasis patents.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS124170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel